Core Viewpoint - Zhongmu Co., Ltd. has shown a positive stock performance with an 18.29% increase year-to-date and a significant rise in net profit for the first nine months of 2025, indicating strong operational growth in the animal health sector [1][2]. Financial Performance - As of September 30, 2025, Zhongmu Co., Ltd. achieved a revenue of 4.442 billion yuan, representing a year-on-year growth of 6.32% [2]. - The net profit attributable to shareholders reached 225 million yuan, marking a substantial increase of 175.49% compared to the previous year [2]. Stock Market Activity - On November 10, 2025, Zhongmu's stock price rose by 2.06% to 7.91 yuan per share, with a trading volume of 71.25 million yuan and a turnover rate of 0.89% [1]. - The company has a total market capitalization of 8.077 billion yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.45% to 36,900, while the average number of circulating shares per person increased by 6.90% to 27,706 shares [2][3]. - The top ten circulating shareholders include significant institutional investors, with notable changes in holdings among major ETFs [3]. Business Overview - Zhongmu Co., Ltd. specializes in animal health products, including vaccines, diagnostic liquids, and veterinary drugs, with a revenue composition of 35.78% from chemical drugs, 27.87% from trade, 19.21% from feed, and 16.10% from biological products [1]. - The company is categorized under the agricultural and animal health sectors, with involvement in various concepts such as small-cap stocks and rural revitalization [1].

Core Viewpoint - Zhongmu Co., Ltd. is a leading enterprise in the domestic animal health industry, focusing on animal health products and nutrition, with a differentiated competitive advantage across the entire industry chain [1] Group 1: Business Performance - In Q3 2025, Zhongmu's revenue reached 4.442 billion, ranking first among 14 companies in the industry, significantly higher than the second-ranked Reap Bio's 2.544 billion [2] - The main business composition includes: chemical drugs 999 million (35.78%), trade 778 million (27.87%), feed 536 million (19.21%), biological products 450 million (16.10%), and others 28.92 million (1.04%) [2] - The net profit for the same period was 230 million, ranking third in the industry, with Reap Bio at 391 million and KQ Bio at 337 million [2] Group 2: Financial Ratios - As of Q3 2025, Zhongmu's debt-to-asset ratio was 28.26%, slightly lower than the previous year's 27.77% and below the industry average of 28.36%, indicating good solvency [3] - The gross profit margin for the same period was 17.07%, slightly down from 17.23% year-on-year, and significantly lower than the industry average of 40.13%, suggesting a need for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.45% to 36,900, while the average number of circulating A-shares held per household increased by 6.90% to 27,700 [5] - Among the top ten circulating shareholders, Guotai Junan CSI Livestock Breeding ETF ranked third with 11.296 million shares, an increase of 4.0293 million shares from the previous period [5] Group 4: Management Compensation - The chairman, Wu Dongxun, saw his salary decrease from 1.545 million in 2023 to 663,000 in 2024, a reduction of 882,000 [4] - The general manager, Li Yin, has a salary of 187,000 for 2024 [4] Group 5: Future Outlook - Analysts expect Zhongmu's revenue and net profit to grow year-on-year in the first half of 2025, driven by the chemical drug segment and improved cost control [5] - Business highlights include potential improvements in livestock health business due to favorable breeding cycles and new business developments in pet health and food brands [5] - Southwest Securities projects EPS for 2025-2027 to be 0.28, 0.34, and 0.38, with a target price of 8.96 based on a 32x PE for 2025 [6]